Unique biology of gliomas: Challenges and opportunities

Trends in Neurosciences

Volumn 35, Issue 9, 2012, Pages 546-556

  Watkins, Stacey ^a   Sontheimer, Harald ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Bradykinin; Clinical trial; Glioma; Glutamate; Ion channel; MGMT

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AFATINIB; AFLIBERCEPT; BEVACIZUMAB; BORTEZOMIB; CEDIRANIB; CETUXIMAB; DASATINIB; ENZASTAURIN; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; LAPATINIB; LENALIDOMIDE; LONAFARNIB; PEGDINETANIB; PERIFOSINE; RAPAMYCIN; SORAFENIB; SUNITINIB; TANDUTINIB; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; UNINDEXED DRUG; VANDETANIB; VATALANIB; XL 147; XL 765;

ANTIANGIOGENIC THERAPY; ASTROCYTE; BRAIN CELL; BRAIN EDEMA; CANCER INHIBITION; CANCER INVASION; CANCER STEM CELL; CELL CYCLE M PHASE; CHEMOTAXIS; DEGENERATIVE DISEASE; DNA METHYLATION; DNA MODIFICATION; ELECTROENCEPHALOGRAM; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; EPIGENETICS; EXCITOTOXICITY; GENE EXPRESSION REGULATION; GLIOMA; GLIOMA CELL; GLIOSIS; HUMAN; NERVE CELL NECROSIS; NONHUMAN; OXIDATIVE STRESS; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; SEIZURE; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

EID: 84865546363     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2012.05.001     Document Type: Review

References (140)

1. Furnari F.B., et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007, 21:2683-2710.
2. Preusser M., et al. Current concepts and management of glioblastoma. Ann. Neurol. 2011, 70:9-21.
3. Porter K.R., et al. Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro Oncol. 2010, 12:520-527.
4. Adamson C., et al. Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin. Investig. Drugs 2009, 18:1061-1083.
5. Chamberlain M.C., Kormanik P.A. Practical guidelines for the treatment of malignant gliomas. West J. Med. 1998, 168:114-120.
6. Mellinghoff I.K., et al. Signal transduction inhibitors and antiangiogenic therapies for malignant glioma. Glia 2011, 59:1205-1212.
7. Cheng L., et al. Elevated invasive potential of glioblastoma stem cells. Biochem. Biophys. Res. Commun. 2011, 406:643-648.
8. Stupp R., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352:987-996.
9. Stupp R., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009, 10:459-466.
10. Wen P.Y., Kesari S. Malignant gliomas in adults. N. Engl. J. Med. 2008, 359:492-507.
11. Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068.
12. Dai C., et al. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev. 2001, 15:1913-1925.
13. Bachoo R.M., et al. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 2002, 1:269-277.
14. Singh S.K., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63:5821-5828.
15. Ignatova T.N., et al. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 2002, 39:193-206.
16. Galli R., et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004, 64:7011-7021.
17. Ge W.P., et al. Local generation of glia is a major astrocyte source in postnatal cortex. Nature 2012, 484:376-380.
18. Tabatabai G., Weller M. Glioblastoma stem cells. Cell Tissue Res. 2011, 343:459-465.
19. Li Z., et al. Turning cancer stem cells inside out: an exploration of glioma stem cell signaling pathways. J. Biol. Chem. 2009, 284:16705-16709.
20. Venere M., et al. Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer's hierarchy. Glia 2011, 59:1148-1154.
21. Sanai N., et al. Neural stem cells and the origin of gliomas. N. Engl. J. Med. 2005, 353:811-822.
22. Siebzehnrubl F.A., et al. The origins of glioma: E Pluribus Unum?. Glia 2011, 59:1135-1147.
23. Plate K.H., et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992, 359:845-848.
24. Ferrara N., Kerbel R.S. Angiogenesis as a therapeutic target. Nature 2005, 438:967-974.
25. Brat D.J., Van Meir E.G. Glomeruloid microvascular proliferation orchestrated by VPF/VEGF: a new world of angiogenesis research. Am. J. Pathol. 2001, 158:789-796.
26. Tugues S., et al. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. Mol. Aspects Med. 2011, 32:88-111.
27. Eichholz A., et al. Anti-angiogenesis therapies: their potential in cancer management. Oncol. Targets Ther. 2010, 3:69-82.
28. Timotheadou E. New agents targeting angiogenesis in glioblastoma. Chemother. Res. Pract. 2011, 2011:878912-878920.
29. Rojiani A.M., Dorovini-Zis K. Glomeruloid vascular structures in glioblastoma multiforme: an immunohistochemical and ultrastructural study. J. Neurosurg. 1996, 85:1078-1084.
30. Soda Y., et al. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:4274-4280.
31. Wang R., et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010, 468:829-833.
32. Ricci-Vitiani L., et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010, 468:824-828.
33. Farin A., et al. Transplanted glioma cells migrate and proliferate on host brain vasculature: a dynamic analysis. Glia 2006, 53:799-808.
34. Zagzag D., et al. Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: one plausible explanation of Scherer's structures. Am. J. Pathol. 2008, 173:545-560.
35. Winkler F., et al. Imaging glioma cell invasion in vivo reveals mechanisms of dissemination and peritumoral angiogenesis. Glia 2009, 57:1306-1315.
36. Watkins S., Sontheimer H. Hydrodynamic cellular volume changes enable glioma cell invasion. J. Neurosci. 2011, 31:17250-17259.
37. Montana V., Sontheimer H. Bradykinin promotes the chemotactic invasion of primary brain tumors. J. Neurosci. 2011, 31:4858-4867.
38. Zhao Y., et al. Study of correlation between expression of bradykinin B2 receptor and pathological grade in human gliomas. Br. J. Neurosurg. 2005, 19:322-326.
39. Wang Y.B., et al. Low dose of bradykinin selectively increases intracellular calcium in glioma cells. J. Neurol. Sci. 2007, 258:44-51.
40. Hsieh H.L., et al. Bradykinin induces matrix metalloproteinase-9 expression and cell migration through a PKC-delta-dependent ERK/Elk-1 pathway in astrocytes. Glia 2008, 56:619-632.
41. Ishiuchi S., et al. Blockage of Ca(2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat. Med. 2002, 8:971-978.
42. Cicardi M., et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N. Engl. J. Med. 2010, 363:532-541.
43. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 2008, 358:1148-1159.
44. Hegi M.E., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005, 352:997-1003.
45. Kunitz A., et al. DNA hypermethylation and aberrant expression of the EMP3 gene at 19q13.3 in human gliomas. Brain Pathol. 2007, 17:363-370.
46. Ochs K., Kaina B. Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent. Cancer Res. 2000, 60:5815-5824.
47. Felsberg J., et al. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int. J. Cancer 2011, 129:659-670.
48. Zschocke J., et al. DNA methylation dependent silencing of the human glutamate transporter EAAT2 gene in glial cells. Glia 2007, 55:663-674.
49. Lehre K.P., et al. Differential expression of two glial glutamate transporters in the rat brain: quantitative and immunocytochemical observations. Exp. Brain Res. 1995, 15:1835-1853.
50. Araque A., et al. Glutamate-dependent astrocyte modulation of synaptic transmission between cultured hippocampal neurons. Eur. J. Neurosci. 1998, 10:2129-2142.
51. Hartley D.M., et al. Glutamate receptor-induced 45Ca2+ accumulation in cortical cell culture correlates with subsequent neuronal degeneration. J. Neurosci. 1993, 13:1993-2000.
52. Brorson J.R., et al. Ca2+ entry via AMPA/KA receptors and excitotoxicity in cultured cerebellar Purkinje cells. J. Neurosci. 1994, 14:187-197.
53. Lee S.G., et al. Oncogene AEG-1 promotes glioma-induced neurodegeneration by increasing glutamate excitotoxicity. Cancer Res. 2011, 71:6514-6523.
54. Lyons S.A., et al. Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res. 2007, 67:9463-9471.
55. Vanhoutte N., Hermans E. Glutamate-induced glioma cell proliferation is prevented by functional expression of the glutamate transporter GLT-1. FEBS Lett. 2008, 582:1847-1852.
56. Ogunrinu T.A., Sontheimer H. Hypoxia increases the dependence of glioma cells on glutathione. J. Biol. Chem. 2010, 285:37716-37724.
57. Kim J.Y., et al. Human cystine/glutamate transporter: cDNA cloning and upregulation by oxidative stress in glioma cells. Biochim. Biophys. Acta 2001, 1512:335-344.
58. Mawatari K., et al. Reactive oxygen species involved in the glutamate toxicity of C6 glioma cells via xc antiporter system. Neuroscience 1996, 73:201-208.
59. Dun Y., et al. Expression of the cystine-glutamate exchanger (xc-) in retinal ganglion cells and regulation by nitric oxide and oxidative stress. Cell Tissue Res. 2006, 324:189-202.
60. Savaskan N.E., et al. Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema. Nat. Med. 2008, 14:629-632.
61. Marcus H.J., et al. In vivo assessment of high-grade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors and cytokines. J. Neurooncol. 2010, 97:11-23.
62. Takano T., et al. Glutamate release promotes growth of malignant gliomas. Nat. Med. 2001, 7:1010-1015.
63. Chung W.J., et al. Inhibition of cystine uptake disrupts the growth of primary brain tumors. J. Neurosci. 2005, 25:7101-7110.
64. Moots P.L., et al. The course of seizure disorders in patients with malignant gliomas. Arch. Neurol. 1995, 52:717-724.
65. van Breemen M.S., et al. Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J. Neurol. 2009, 256:1519-1526.
66. Sontheimer H. Glutamate and tumor-associated epilepsy. Oncotargets 2011, 2:823-824.
67. Buckingham S.C., et al. Glutamate release by primary brain tumors induces epileptic activity. Nat. Med. 2011, 17:1269-1274.
68. Piao Y., et al. AMPA receptors promote perivascular glioma invasion via beta1 integrin-dependent adhesion to the extracellular matrix. Neuro Oncol. 2009, 11:260-273.
69. Dong X.X., et al. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol. Sin. 2009, 30:379-387.
70. Kim K., et al. Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics. J. Cell. Physiol. 2011, 226:2484-2493.
71. de Groot J., Sontheimer H. Glutamate and the biology of gliomas. Glia 2010, 59:1181-1189.
72. Higashimori H., Sontheimer H. Role of Kir4.1 channels in growth control of glia. Glia 2007, 55:1668-1679.
73. Chittajallu R., et al. Regulation of Kv1 subunit expression in oligodendrocyte progenitor cells and their role in G1/S phase progression of the cell cycle. Proc. Natl. Acad. Sci. U.S.A. 2002, 19:2350-2355.
74. Vautier F., et al. Shaker-type potassium channel subunits differentially control oligodendrocyte progenitor proliferation. Glia 2004, 48:337-345.
75. Kunzelmann K. Ion channels and cancer. J. Membr. Biol. 2005, 205:159-173.
76. Cuddapah V.A., Sontheimer H. Ion channels and the control of cancer cell migration. Am. J. Physiol. Cell Physiol. 2011, 301:C541-C549.
77. Habela C.W., et al. Chloride accumulation drives volume dynamics underlying cell proliferation and migration. J. Neurophysiol. 2009, 101:750-757.
78. Ernest N.J., et al. Relative contribution of chloride channels and transporters to regulatory volume decrease in human glioma cells. Am. J. Physiol. Cell Physiol. 2005, 288:C1451-C1460.
79. Habela C.W., Sontheimer H. Cytoplasmic volume condensation is an integral part of mitosis. Cell Cycle 2007, 6:1613-1620.
80. Habela C.W., et al. ClC3 is a critical regulator of the cell cycle in normal and malignant glial cells. J. Neurosci. 2008, 28:9205-9217.
81. Cuddapah V.A., et al. Kinase activation of ClC-3 accelerates cytoplasmic condensation during mitotic cell rounding. Am. J. Physiol. Cell Physiol. 2011, 302:C527-C538.
82. Weaver A.K., et al. Expression and function of calcium-activated potassium channels in human glioma cells. Glia 2006, 54:223-233.
83. Weaver A.K., et al. Role for calcium-activated potassium channels (BK) in growth control of human malignant glioma cells. J. Neurosci. Res. 2004, 78:224-234.
84. McCoy E., Sontheimer H. Expression and function of water channels (aquaporins) in migrating malignant astrocytes. Glia 2007, 55:1034-1043.
85. Bomben V.C., et al. Transient receptor potential canonical channels are essential for chemotactic migration of human malignant gliomas. J. Cell. Physiol. 2011, 226:1879-1888.
86. Haas B.R., Sontheimer H. Inhibition of the sodium-potassium-chloride cotransporter isoform-1 reduces glioma invasion. Cancer Res. 2010, 70:5597-5606.
87. Ransom C.B., et al. Volume-activated chloride currents contribute to the resting conductance and invasive migration of human glioma cells. J. Neurosci. 2001, 21:7674-7683.
88. Cuddapah V.A., Sontheimer H. Molecular interaction and functional regulation of ClC-3 by Ca2+/calmodulin-dependent protein kinase II (CaMKII) in human malignant glioma. J. Biol. Chem. 2010, 15:11188-11196.
89. Lui V.C., et al. Invasion of human glioma cells is regulated by multiple chloride channels including ClC-3. Anticancer Res. 2010, 30:4515-4524.
90. Mamelak A.N., et al. Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. J. Clin. Oncol. 2006, 24:3644-3650.
91. Haas B.R., et al. With-No-Lysine Kinase 3 (WNK3) stimulates glioma invasion by regulating cell volume. Am. J. Physiol. Cell Physiol. 2011, 301:C1150-C1160.
92. Sampson J.H., et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol. 2011, 13:324-333.
93. Razis E., et al. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment. Clin. Cancer Res. 2009, 15:6258-6266.
94. Friedman H.S., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 2009, 27:4733-4740.
95. Kreisl T.N., et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 2009, 27:740-745.
96. Brada M., et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann. Oncol. 2001, 12:259-266.
97. Narayana A., et al. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J. Neurosurg. 2011, 116:341-345.
98. Vredenburgh J.J., et al. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin. Cancer Res. 2011, 17:4119-4124.
99. Lai A., et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol. 2011, 29:142-148.
100. Reardon D.A., et al. Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. J. Neurooncol. 2012, 107:213-221.
101. Lucio-Eterovic A.K., et al. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin. Cancer Res. 2009, 15:4589-4599.
102. Keunen O., et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:3749-3754.
103. Robinson C.G., et al. Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival. Br. J. Cancer 2010, 103:498-504.
104. Robe P.A., et al. Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults. BMC Cancer 2009, 9:372.
105. Howes J.F., Bell C. Talampanel. Neurotherapeutics 2007, 4:126-129.
106. Iwamoto F.M., et al. Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas. Cancer 2010, 116:1776-1782.
107. Grossman S.A., et al. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. J. Clin. Oncol. 2009, 27:4155-4161.
108. Grossman S.A., et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin. Cancer Res. 2010, 16:2443-2449.
109. + ion channel blockers. J. Neurosci. 1999, 19:5942-5954.
110. Deshane J., et al. Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2. J. Biol. Chem. 2003, 278:4135-4144.
111. Lyons S.A., et al. Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. Glia 2002, 39:162-173.
112. Wick W., et al. Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro Oncol. 2011, 13:566-579.
113. Golde T.E. The therapeutic importance of understanding mechanisms of neuronal cell death in neurodegenerative disease. Mol. Neurodegener. 2009, 4:8-15.
114. Gorman A.M. Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling. J. Cell. Mol. Med. 2008, 12:2263-2280.
115. Ye Z.C., Sontheimer H. Glioma cells release excitotoxic concentrations of glutamate. Cancer Res. 1999, 59:4383-4391.
116. Lecrux C., Hamel E. The neurovascular unit in brain function and disease. Acta Physiol. 2011, 203:47-59.
117. Zhong Z., et al. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat. Neurosci. 2008, 11:420-422.
118. Grammas P., et al. Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases. Expert Rev. Mol. Med. 2011, 13:e19-e41.
119. Jain R.K., et al. Angiogenesis in brain tumours. Nat. Rev. Neurosci. 2007, 8:610-622.
120. Scarmeas N., et al. Seizures in Alzheimer disease: who, when, and how common?. Arch. Neurol. 2009, 66:992-997.
121. Kelley B.J., Rodriguez M. Seizures in patients with multiple sclerosis: epidemiology, pathophysiology and management. CNS Drugs 2009, 23:805-815.
122. Trapp B.D., Nave K.A. Multiple sclerosis: an immune or neurodegenerative disorder?. Annu. Rev. Neurosci. 2008, 31:247-269.
123. Zlokovic B.V. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat. Rev. Neurosci. 2011, 12:723-738.
124. Hynd M.R., et al. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem. Int. 2004, 45:583-595.
125. Raymond L.A., et al. Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. Neuroscience 2011, 198:252-273.
126. Ferraiuolo L., et al. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2011, 7:616-630.
127. Hardy J., Orr H. The genetics of neurodegenerative diseases. J. Neurochem. 2006, 97:1690-1699.
128. Huse J.T., et al. Molecular subclassification of diffuse gliomas: seeing order in the chaos. Glia 2011, 59:1190-1199.
129. Jomova K., et al. Metals, oxidative stress and neurodegenerative disorders. Mol. Cell. Biochem. 2010, 345:91-104.
130. Reuter S., et al. Oxidative stress, inflammation, and cancer: how are they linked?. Free Radic. Biol. Med. 2010, 49:1603-1616.
131. Pekny M., Nilsson M. Astrocyte activation and reactive gliosis. Glia 2005, 50:427-434.
132. Charles N.A., et al. The brain tumor microenvironment. Glia 2011, 59:1169-1180.
133. Katz A.M., et al. Astrocyte-specific expression patterns associated with the PDGF-induced glioma microenvironment. PLoS ONE 2012, 7:e32453-e32465.
134. Olsen M.L., Sontheimer H. Mislocalization of Kir channels in malignant glia. Glia 2004, 46:63-73.
135. Ye Z.C., et al. Compromised glutamate transport in human glioma cells: reduction- mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange. J. Neurosci. 1999, 19:10767-10777.
136. Turcan S., et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012, 483:479-483.
137. Demuth T., Berens M.E. Molecular mechanisms of glioma cell migration and invasion. J. Neurooncol. 2004, 70:217-228.
138. Munson J.M., et al. Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma. Sci. Transl. Med. 2012, 4:127ra36.
139. Oka A., et al. Vulnerability of oligodendroglia to glutamate: pharmacology, mechanisms, and prevention. J. Neurosci. 1993, 13:1441-1453.
140. Yang I., et al. The role of microglia in central nervous system immunity and glioma immunology. J. Clin. Neurosci. 2010, 17:6-10.